Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Study sponsor: Relay Therapeutics, Inc. · RLAY
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-04-30Estimated
Enrollment · participants540Estimated
Source updated2026-11-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.